LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide.
$80.89-3.11%
报价 2026-11-06
市值
$1.85B
EV
$2.61B
PE (TTM)
42.4x
预期 PE (FY2026)
28.5x
52 周区间距高点 -31.1%
$78.80$117.39
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.1x | 2.75 → 3.17（1.2x） | 25.5 |
| FY+32028-12 | 1.2x | 2.75 → 3.46（1.3x） | 23.4 |
毛利率 72% · TTM 收入 $269M · 基数 EPS 2.75（调整后）
电话会信号
辅助标签Q3 20262026-11-04
扩产需求加速下调/撤回指引供不应求
指引 下调
信心 4
分析师 3
“We expect 2027 approvals in Korea and India and plan to apply to the PMDA in Japan this quarter.”
原文引用（4）
- 扩产：We also recently expanded our Burlington footprint by adding a 30,000 sq ft building.
- 需求加速：we are getting so much demand for cardiac allografts
- 下调/撤回指引：we're coming back to you now and saying, 'Okay, we're going to do 11% next quarter in Q4.'
- 供不应求：we could have sold a lot more if we had been able to approve, or quality-wise, approve of all the products
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| LMATLeMaitre Vascular, Inc. | $1.85B | -3.1% | +13.0% | 71.5% | 42.4x | 28.8x | 24.8x | |
| TWSTTwist Bioscience Corporation | $7.95B | +0.1% | +20.2% | 52.8% | – | – | – | |
| HAEHaemonetics Corporation | $5.46B | -3.4% | +7.0% | 59.8% | 58.9x | 24.8x | 18.9x | |
| ACHCAcadia Healthcare Company, Inc. | $3.44B | +6.4% | +4.2% | 19.3% | – | – | 37.7x | |
| NHCNational HealthCare Corporation | $3.27B | +0.6% | – | – | – | – | – | |
| ATRCAtriCure, Inc. | $2.98B | -4.5% | +13.7% | 77.3% | 194.5x | 73.5x | 51.4x | GARP |
| AVAHAveanna Healthcare Holdings Inc. | $2.89B | -3.1% | +11.5% | 32.6% | 10.3x | 14.2x | 18.0x | GARP |
| INSPInspire Medical Systems, Inc. | $1.85B | -3.8% | -5.9% | 85.5% | 14.8x | 22.8x | 17.1x | |
| PAHCPhibro Animal Health Corporation | $1.34B | -6.9% | +3.5% | 33.2% | 13.5x | 8.6x | 104.8x | |
| 同行中位数 | – | – | +7.0% | 52.8% | 14.8x | 22.8x | 28.3x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-09-30 Q3 2026 | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $68M | $70.4M | $66.6M | $64.5M | $61M | $64.2M | $59.9M | $55.7M |
| Gross Margin | 71.7% | 72.1% | 72.7% | 71.7% | 75.3% | 70% | 69.2% | 69.3% |
| Operating Margin | 26% | 29% | 26.7% | 29.2% | 33.3% | 25.1% | 21.1% | 23.1% |
| Net Income | $15M | $17.1M | $15.7M | $15.6M | $17.4M | $13.8M | $11M | $11.2M |
| Diluted EPS | 0.65 | 0.74 | 0.68 | 0.68 | 0.75 | 0.6 | 0.48 | 0.49 |
| Operating Cash Flow | $22M | $16M | $15.1M | $23.2M | $28.8M | $20.3M | $9M | $15.2M |